Beyond Amyloid. The Future of Therapeutics for Alzheimer's Disease

Advances in Pharmacology

Volumn 64, Issue , 2012, Pages 213-271

  Lane, Rachel F ^a   Shineman, Diana W ^a   Steele, John W ^b   Lee, Linda Bobbi H ^c   Fillit, Howard M ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; AMYLOID; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BAPINEUZUMAB; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; BSM 708163; CAD 106; CHF 5074; CHF5074; CRENEZUMAB; CTS 21166; CTS21166; DAVUNETIDE; EHT 0202; ELND005; EVP 6124; EVT 302; GAMMA SECRETASE; GANTENERUMAB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOMODULATING AGENT; ISPRONICLINE; NIC5 15; PBT2; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PRESENILIN 1; RO5313534; SCH 745966; SCH745966; SEMAGACESTAT; ST101; SYN 114; TAU PROTEIN; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPHAGY; BLOOD BRAIN BARRIER; CELL MIGRATION; CHOLINERGIC ACTIVITY; COGNITION; DRUG DEVELOPMENT; ENDOSOME; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOTHERAPY; INFLAMMATION; LYSOSOME; METABOLIC DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; SYNAPSE; SYNAPTIC MEMBRANE;

EID: 84864318274     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394816-8.00007-6     Document Type: Chapter

References (278)

1. Abbatecola A.M., Lattanzio F., Molinari A.M., Cioffi M., Mansi L., Rambaldi P., et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 2010, 33:1706-1711.
2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine (United States) 2008, 358:2545-2559.
3. Alberini C.M. The role of reconsolidation and the dynamic process of long-term memory formation and storage. Frontiers in Behavioral Neuroscience (Switzerland) 2011, 5:12.
4. Aleshkov S., Abraham C.R., Zannis V.I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). relevance to Alzheimer's disease. Biochemistry (United States) 1997, 36:10571-10580.
5. Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America (United States) 2005, 102:13461-13466.
6. Andrews-Zwilling Y., Bien-Ly N., Xu Q., Li G., Bernardo A., Yoon S.Y., et al. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. Journal of Neuroscience 2010, 13(41(30)):13707-13717.
7. Angelopoulos P., Agouridaki H., Vaiopoulos H., Siskou E., Doutsou K., Costa V., et al. Cytokines in Alzheimer's disease and vascular dementia. International Journal of Neuroscience (United States) 2008, 118:1659-1672.
8. Aoki K., Uchihara T., Nakamura A., Komori T., Arai N., Mizutani T. Expression of apolipoprotein E in ballooned neurons-comparative immunohistochemical study on neurodegenerative disorders and infarction. Acta Neuropathologica (Germany) 2003, 106:436-440.
9. Arendt T. Synaptic degeneration in Alzheimer's disease 2009, 118:167-179.
10. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. Journal of Neuroscience 2007, 27:9115-9129.
11. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., et al. Non-fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. Journal of Neuroscience (United States) 2002, 22:7873-7878.
12. Bai L., Wang Y., Fan J., Chen Y., Ji W., Qu A., et al. Dissecting multiple steps of GLUT4 trafficking and identifying the sites of insulin action. Cell Metabolism (United States) 2007, 5:47-57.
13. Balakrishnan K., Andrei-Selmer L.C., Selmer T., Bacher M., Dodel R. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. Journal of Alzheimer's Disease (Netherlands) 2010, 20:135-143.
14. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Journal of Neuroscience (United States) 2009, 29:6771-6779.
15. Bertram L., Tanzi R.E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nature reviews. Neuroscience (England) 2008, 9:768-778.
16. Bettcher B.M., Wilheim R., Rigby T., Green R., Miller J.W., Racine C.A., et al. C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain, Behavior, and Immunity (United States) 2012, 26:103-108.
17. Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease 2008, 31:454-463.
18. Bohm C., Seibel N.M., Henkel B., Steiner H., Haass C., Hampe W. SorLA signaling by regulated intramembrane proteolysis. Journal of Biological Chemistry (United States) 2006, 281:14547-14553.
19. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Experimental Neurology 2010, 224:472-485.
20. Bolten C.W., Blanner P.M., McDonald W.G., Staten N.R., Mazzarella R.A., Arhancet G.B., et al. Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma. Gene Regulation and Systems Biology 2007, 1:73-82.
21. Bonaventure P., Letavic M., Dugovic C., Wilson S., Aluisio L., Pudiak C., et al. Histamine H3 receptor antagonists: from target identification to drug leads. Biochemical Pharmacology 2007, 73:1084-1096.
22. Bouras C., Riederer B.M., Kovari E., Hof P.R., Giannakopoulos P. Humoral immunity in brain aging and Alzheimer's disease. Brain Research. Brain Research Reviews (Netherlands) 2005, 48:477-487.
23. Boyd T.D., Bennett S.P., Mori T., Governatori N., Runfeldt M., Norden M., et al. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. Journal of Alzheimer's Disease (Netherlands) 2010, 21:507-518.
24. Braak H., Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiology of Aging (United States) 1997, 18:S85-S88.
25. Bradford H.F., Foley P., Docherty M., Fillit H., Luine V.N., McEwen B., et al. Antibodies in serum of patients with Alzheimer's disease cause immunolysis of cholinergic nerve terminals from the rat cerebral cortex. Canadian Journal of Neurological Sciences (Canada) 1989, 16:528-534.
26. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. Journal of Neuroscience (United States) 2004, 24:2527-2534.
27. Brunden K.R., Zhang B., Carroll J., Yao Y., Potuzak J.S., Hogan A.M., et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. Journal of Neuroscience (United States) 2010, 30:13861-13866.
28. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews. Neuroscience (England) 2009, 10:333-344.
29. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of General Psychiatry (United States) 2012, 69:98-106.
30. Buchhave P., Zetterberg H., Blennow K., Minthon L., Janciauskiene S., Hansson O. Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiology of Aging (United States) 2010, 31:1877-1884.
31. Bulic B., Pickhardt M., Schmidt B., Mandelkow E.M., Waldmann H., Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angewandte Chemie (International ed. in English) 2009, 48:1740-1752.
32. Calissano P., Matrone C., Amadoro G. Apoptosis and in vitro Alzheimer disease neuronal models. Communicative & Integrative Biology (United States) 2009, 2:163-169.
33. Cameron B., Landreth G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiology of Disease (United States) 2010, 37:503-509.
34. Cao D., Lu H., Lewis T.L., Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. Journal of Biological Chemistry (United States) 2007, 282:36275-36282.
35. Castano E.M., Prelli F., Wisniewski T., Golabek A., Kumar R.A., Soto C., et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochemical Journal (England) 1995, 306(Pt 2):599-604.
36. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science Translational Medicine (United States) 2011, 3:89ra57.
37. Cataldo A.M., Barnett J.L., Pieroni C., Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. Journal of Neuroscience (United States) 1997, 17:6142-6151.
38. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and down syndrome: Differential effects of APOE genotype and presenilin mutations. American Journal of Pathology (United States) 2000, 157:277-286.
39. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., et al. Abeta localization in abnormal endosomes: Association with earliest Abeta elevations in AD and down syndrome. Neurobiology of Aging (United States) 2004, 25:1263-1272.
40. Cerf E., Gustot A., Goormaghtigh E., Ruysschaert J.M., Raussens V. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB Journal (United States) 2011, 25:1585-1595.
41. Chang S., ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W., Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America (United States) 2005, 102:18694-18699.
42. Chen D.Y., Stern S.A., Garcia-Osta A., Saunier-Rebori B., Pollonini G., Bambah-Mukku D., et al. A critical role for IGF-II in memory consolidation and enhancement. Nature (England) 2011, 469:491-497.
43. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y.D., Ma T., et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3907-3912.
44. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacology & Therapeutics (England) 2010, 128:519-548.
45. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biology 2009, 11:909-913.
46. Cohen T.J., Guo J.L., Hurtado D.E., Kwong L.K., Mills I.P., Trojanowski J.Q., et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nature Communication 2011, 2:252.
47. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (United States) 1993, 261:921-923.
48. Craft S., Watson G.S. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurology 2004, 3:169-178.
49. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Archives of Neurology 2012, 69:29-38.
50. Cunningham C. Systemic inflammation and delirium: Important co-factors in the progression of dementia. Biochemical Society Transactions (England) 2011, 39:945-953.
51. Day J.J., Sweatt J.D. Epigenetic mechanisms in cognition. Neuron 2011, 70:813-829.
52. De Strooper B. Aph-1, pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron (United States) 2003, 38:9-12.
53. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Journal of Clinical Investigation (United States) 2008, 118:4002-4013.
54. Deinhardt K., Kim T., Spellman D.S., Mains R.E., Eipper B.A., Neubert T.A., et al. Neuronal growth cone retraction relies on proneurotrophin receptor signaling through rac. Science Signaling (United States) 2011, 4:ra82.
55. Deinhardt K., Salinas S., Verastegui C., Watson R., Worth D., Hanrahan S., et al. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron (United States) 2006, 52:293-305.
56. Dickey C.A., Dunmore J., Lu B., Wang J.W., Lee W.C., Kamal A., et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB Journal 2006, 20:753-755.
57. Diniz B.S., Teixeira A.L., Ojopi E.B., Talib L.L., Mendonca V.A., Gattaz W.F., et al. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. Journal of Alzheimer's Disease (Netherlands) 2010, 22:1305-1311.
58. Dodart J.C., Marr R.A., Koistinaho M., Gregersen B.M., Malkani S., Verma I.M., et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America (United States) 2005, 102:1211-1216.
59. Dodson S.E., Gearing M., Lippa C.F., Montine T.J., Levey A.I., Lah J.J. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. Journal of Neuropathology and Experimental Neurology (United States) 2006, 65:866-872.
60. Dolan P.J., Johnson G.V. The role of tau kinases in Alzheimer's disease. Current Opinion in Drug Discovery & Development 2010, 13:595-603.
61. Donkin J.J., Stukas S., Hirsch-Reinshagen V., Namjoshi D., Wilkinson A., May S., et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. Journal of Biological Chemistry (United States) 2010, 285:34144-34154.
62. Dumanis S.B., Cha H.J., Song J.M., Trotter J.H., Spitzer M., Lee J.Y., et al. ApoE receptor 2 regulates synapse and dendritic spine formation. PLoS One (United States) 2011, 6:e17203.
63. Erbel-Sieler C., Dudley C., Zhou Y., Wu X., Estill S.J., Han T., et al. Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proceedings of the National Academy of Sciences of the United States of America (United States) 2004, 101:13648-13653.
64. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. Journal of Clinical Investigation (United States) 2003, 112:440-449.
65. Fandrich M. Oligomeric intermediates in amyloid formation: Structure determination and mechanisms of toxicity. Journal of Molecular Biology 2012, EPUB ahead of print.
66. Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., et al. PBT2 rapidly improves cognition in Alzheimer's disease: Additional phase II analyses. Journal of Alzheimer's Disease (Netherlands) 2010, 20:509-516.
67. de Calignon A., Polydoro M., Suárez-Calvet M., William C., Adamowicz D.H., Kopeikina K.J., et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73(4):685-697.
68. Fillit H. Intravenous immunoglobulins for Alzheimer's disease. Lancet Neurology (England) 2004, 3:704.
69. Fillit H., Ding W.H., Buee L., Kalman J., Altstiel L., Lawlor B., et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neuroscience Letters (Netherlands) 1991, 129:318-320.
70. Fillit H.M., Kemeny E., Luine V., Weksler M.E., Zabriskie J.B. Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer's type. Journal of Gerontology (United States) 1987, 42:180-184.
71. Finan G.M., Okada H., Kim T.W. BACE1 retrograde trafficking is uniquely regulated by the cytoplasmic domain of sortilin. Journal of Biological Chemistry 2011, 286(14):12602.
72. Fishel M.A., Watson G.S., Montine T.J., Wang Q., Green P.S., Kulstad J.J., et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Archives of Neurology 2005, 62:1539-1544.
73. Fitzpatrick C.J., Lombroso P.J. The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition. Frontiers in Neuroanatomy 2011, 5:47.
74. Fjorback A.W., Seaman M., Gustafsen C., Mehmedbasic A., Gokool S., Wu C., et al. Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. Journal of Neuroscience 2012, 32:1467-1480.
75. Foley P., Bradford H.F., Docherty M., Fillit H., Luine V.N., McEwen B., et al. Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease. Journal of Neurology (Germany, West) 1988, 235:466-471.
76. Forlenza O.V., Diniz B.S., Radanovic M., Santos F.S., Talib L.L., Gattaz W.F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. British Journal of Psychiatry 2011, 198:351-356.
77. Frasca D., Blomberg B.B. Aging affects human B cell responses. Journal of Clinical Immunology (Netherlands) 2011, 31:430-435.
78. Gandy S. Neurohormonal signaling pathways and the regulation of Alzheimer beta-amyloid precursor metabolism. Trends in Endocrinology and Metabolism 1999, 10:273-279.
79. Gandy S., Simon A.J., Steele J.W., Lublin A.L., Lah J.J., Walker L.C., et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Annals of Neurology (United States) 2010, 68:220-230.
80. Garcia de Yebenes E., Ho A., Damani T., Fillit H., Blum M. Regulation of the heparan sulfate proteoglycan, perlecan, by injury and interleukin-1alpha. Journal of Neurochemistry (United States) 1999, 73:812-820.
81. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Annals of the New York Academy of Sciences 2000, 920:321-327.
82. Ginsberg S.D., Mufson E.J., Alldred M.J., Counts S.E., Wuu J., Nixon R.A., et al. Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Chemical Neuroanatomy (Netherlands) 2011, 42:102-110.
83. Ginsberg S.D., Alldred M.J., Counts S.E., Cataldo A.M., Neve R.L., Jiang Y., et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biological Psychiatry (United States) 2010, 68:885-893.
84. Ginsberg S.D., Mufson E.J., Counts S.E., Wuu J., Alldred M.J., Nixon R.A., et al. Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's Disease (Netherlands) 2010, 22:631-639.
85. Glabe C.G. Structural classification of toxic amyloid oligomers. Journal of Biological Chemistry (United States) 2008, 283:29639-29643.
86. Goodarzi M.O., Lehman D.M., Taylor K.D., Guo X., Cui J., Quinones M.J., et al. SORCS1: A novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes (United States) 2007, 56:1922-1929.
87. Gorelick P.B. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences (United States) 2010, 1207:155-162.
88. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: Native subtypes and their relevance. Trends in Pharmacological Sciences 2006, 27:482-491.
89. Gotz J., Deters N., Doldissen A., Bokhari L., Ke Y., Wiesner A., et al. A decade of tau transgenic animal models and beyond. Brain Pathology (Switzerland) 2007, 17:91-103.
90. Gozes I., Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. Journal of Alzheimer's Disease 2004, 6:S37-S41.
91. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau 2008, 28:11500-11510.
92. Greig N.H., Giordano T., Zhu X., Yu Q.S., Perry T.A., Holloway H.W., et al. Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiologiae Experimentalis (Wars) (Poland) 2004, 64:1-9.
93. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
94. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nature Medicine 2008, 14:894.
95. Hampel H., Ewers M., Burger K., Annas P., Mortberg A., Bogstedt A., et al. Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. Journal of Clinical Psychiatry 2009, 70:922-931.
96. Hansen R.A., Gartlehner G., Lohr K.N., Kaufer D.I. Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis. Drugs Aging 2007, 24:155-167.
97. Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America (United States) 2003, 100:10966-10971.
98. Harris H., Rubinsztein D.C. Control of autophagy as a therapy for neurodegenerative disease. Nature Reviews. Neurology 2011, 8(2):108.
99. Hauser P.S., Narayanaswami V., Ryan R.O. Apolipoprotein E: From lipid transport to neurobiology. Progress in Lipid Research (England) 2011, 50:62-74.
100. Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272:827-829.
101. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
102. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet (England) 2008, 372:216-223.
103. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology (United States) 2009, 73:768-774.
104. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Patents on CNS Drug Discovery 2010, 5:109-117.
105. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: The challenge of the second century. Science Translational Medicine 2011, 3:77sr1.
106. Hong M., Lee V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. Journal of Biological Chemistry 1997, 272:19547-19553.
107. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. Journal of Biological Chemistry 1997, 272:25326-25332.
108. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
109. Hu F., Padukkavidana T., Vaegter C.B., Brady O.A., Zheng Y., Mackenzie I.R., et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron (United States) 2010, 68:654-667.
110. Hu Y.S., Xu P., Pigino G., Brady S.T., Larson J., Lazarov O. Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 mice. FASEB Journal (United States) 2010, 24:1667-1681.
111. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proceedings of the National Academy of Sciences of the United States of America (United States) 2001, 98:8838-8843.
112. Hurley D. News from the society for neuroscience annual meeting: Diabetes drug liraglutide set for clinical trials of Alzheimer disease on promise of animal studies. Neurology Today 2012, 12:11-12.
113. Hutton M., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
114. Ikegami S., Harada A., Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neuroscience Letters 2000, 279:129-132.
115. Iqbal K., Grundke-Iqbal I. Tau phosphatase activity as a therapeutic target for AD. Drug News & Perspectives 1998, 11:10-14.
116. Jack C.R., Petersen R.C., Xu Y.C., Waring S.C., O'Brien P.C., Tangalos E.G., et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997, 49:786-794.
117. Jiang H., Hampel H., Prvulovic D., Wallin A., Blennow K., Li R., et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Molecular Neurodegeneration (England) 2011, 6:69.
118. Johnson R.L., Huang W., Huang R., Crowe A., Ballatore C., Trojanowski J.Q., et al. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Probe reports from the NIH molecular libraries program, 2009-2010 (May 18th 2010) 2010.
119. Jones P.B., Adams K.W., Rozkalne A., Spires-Jones T.L., Hshieh T.T., Hashimoto T., et al. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. PLoS One 2011, 31(1):6. e14586.
120. Josephs K.A., Tsuboi Y., Cookson N., Watt H., Dickson D.W. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Archives of Neurology (United States) 2004, 61:1579-1584.
121. Kaden D., Bush A.I., Danzeisen R., Bayer T.A., Multhaup G. Disturbed copper bioavailability in Alzheimer's disease. International Journal of Alzheimer's Disease (United States) 2011, 2011:345614.
122. Kellner A., Matschke J., Bernreuther C., Moch H., Ferrer I., Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Annals of Neurology (United States) 2009, 65:24-31.
123. Kim J., Jiang H., Park S., Eltorai A.E., Stewart F.R., Yoon H., et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. Journal of Neuroscience (United States) 2011, 31:18007-18012.
124. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacological Reviews 2008, 60:470-512.
125. Koga H., Kaushik S., Cuervo A.M. Protein homeostasis and aging: The importance of exquisite quality control. Ageing Research Reviews (England) 2011, 10:205-215.
126. Korde A.S., Pettigrew L.C., Craddock S.D., Maragos W.F. The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia. Journal of Neurochemistry 2005, 94:1676-1684.
127. Kounnas M.Z., et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (United States) 2010, 67:769-780.
128. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to beta-amyloid. Journal of Biological Chemistry (United States) 1994, 269:23403-23406.
129. Lane R.F., Raines S.M., Steele J.W., Ehrlich M.E., Lah J.A., Small S.A., et al. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: Evidence for involvement of SorL1 and the retromer complex. Journal of Neuroscience (United States) 2010, 30:13110-13115.
130. Lane R.F., Shineman D.W., Fillit H.M. Beyond amyloid: A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias. Alzheimer's Research & Therapy 2011, 3:36.
131. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurology (England) 2008, 7:779-786. PBT2-201-EURO study group.
132. Lanz T.A., Carter D.B., Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiology of Disease (United States) 2003, 13:246-253.
133. Laskowitz D.T., Song P., Wang H., Mace B., Sullivan P.M., Vitek M.P., et al. Traumatic brain injury exacerbates neurodegenerative pathology: Improvement with an apolipoprotein E-based therapeutic. Journal of Neurotrauma (United States) 2010, 27:1983-1995.
134. Le C.S., Klafki H.W., Plesnila N., Hubinger G., Obermeier A., Sahagun H., et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:9673-9678.
135. Lee J.H., Yu W.H., Kumar A., Lee S., Mohan P.S., Peterhoff C.M., et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell (United States) 2010, 141:1146-1158.
136. Lee S.W., Clemenson G.D., Gage F.H. New neurons in an aged brain. Behavioural Brain Research 2011, 227(2):497.
137. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Progress in Brain Research (Netherlands) 2009, 175:83-93.
138. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature (England) 2006, 440:352-357.
139. Leveugle B., Ding W., Buee L., Fillit H.M. Interleukin-1 and nerve growth factor induce hypersecretion and hypersulfation of neuroblastoma proteoglycans which bind beta-amyloid. Journal of Neuroimmunology (Netherlands) 1995, 60:151-160.
140. Levin E.C., Acharya N.K., Han M., Zavareh S.B., Sedeyn J.C., Venkataraman V., et al. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Research (Netherlands) 2010, 1345:221-232.
141. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. Journal of Alzheimer's Disease 2010, 19:1205-1219.
142. Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., et al. Trans-synaptic spead of tau pathology in vivo. PLoS One 2012, 7(2):e31302.
143. Liang X., Slifer M., Martin E.R., Schnetz-Boutaud N., Bartlett J., Anderson B., et al. Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10. Human Mutation (United States) 2009, 30:463-471.
144. Liu D., Pitta M., Mattson M.P. Preventing NAD(+) depletion protects neurons against excitotoxicity: Bioenergetic effects of mild mitochondrial uncoupling and caloric restriction. Annals of the New York Academy of Sciences 2008, 1147:275-282.
145. Liu J., Lamb D., Chou M.M., Liu Y.J., Li G. Nerve growth factor-mediated neurite outgrowth via regulation of Rab5. Molecular Biology of the Cell (United States) 2007, 18:1375-1384.
146. Lopez-Arrieta J.M., Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database of Systematic Reviews 2002 page CD000147 2002.
147. Lopez-Tobon A., Castro-Alvarez J.F., Piedrahita D., Boudreau R.L., Gallego-Gomez J.C., Cardona-Gomez G.P. Silencing of CDK5 as potential therapy for Alzheimer's disease. Reviews in the Neurosciences 2011, 22:143-152.
148. Lu P.J., Wulf G., Zhou X.Z., Davies P., Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999, 399:784-788.
149. Macintyre G., Alford T., Xiong L., Rouleau G.A., Tibbo P.G., Cox D.W. Association of NPAS3 exonic variation with schizophrenia. Schizophrenia Research (Netherlands) 2010, 120:143-149.
150. Mahley R.W., Huang Y. Apolipoprotein (apo) E4 and Alzheimer's disease: Unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurologica Scandinavica. Supplementum (Denmark) 2006, 185:8-14.
151. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. Journal of Lipid Research (United States) 2009, 50(Suppl):S183-S188.
152. Mancinella A., Mancinella M., Carpinteri G., Bellomo A., Fossati C., Gianturco V., et al. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Archives of Gerontology and Geriatrics (Netherlands) 2009, 49(Suppl. 1):185-194.
153. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer's disease: Clinical trials and drug development. Lancet Neurology 2010, 9:702-716.
154. Martinez M., Brice A., Vaughan J.R., Zimprich A., Breteler M.M., Meco G., et al. Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for parkinson's disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics (United States) 2005, 136B:72-74.
155. Masterman T., Hillert J. The telltale scan: APOE epsilon4 in multiple sclerosis. Lancet Neurology (England) 2004, 3:331.
156. Matrone C., Di Luzio A., Meli G., D'Aguanno S., Severini C., Ciotti M.T., et al. Activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells. Journal of Alzheimer's Disease (Netherlands) 2008, 13:81-96.
157. Matsuoka Y., Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P., et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience 2007, 31:165-170.
158. Matsuzaki M., Honkura N., Ellis-Davies G.C., Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature (England) 2004, 429:761-766.
159. Mattson M.P., Barger S.W., Furukawa K., Bruce A.J., Wyss-Coray T., Mark R.J., et al. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain research. Brain research reviews (Netherlands) 1997, 23:47-61.
160. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry (England) 2003, 27:741-749.
161. McGough I.J., Cullen P.J. Recent advances in retromer biology. Traffic (Denmark) 2011, 12:963-971.
162. McManus M.J., Murphy M.P., Franklin J.L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 2011, 31:15703-15715.
163. Medina M., Garrido J.J., Wandosell F.G. Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Frontiers in Molecular Neuroscience 2011, 4:24.
164. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: New biomarkers and treatment targets?. Neuromolecular Medicine (United States) 2010, 12:331-340.
165. Min S.W., Cho S.H., Zhou Y., Schroeder S., Haroutunian V., Seeley W.W., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67:953-966.
166. Mohs R.C., Shiovitz T.M., Tariot P.N., Porsteinsson A.P., Baker K.D., Feldman P.D. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. American Journal of Geriatric Psychiatry 2009, 17:752-759.
167. Moir R.D., Tseitlin K.A., Soscia S., Hyman B.T., Irizarry M.C., Tanzi R.E. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. Journal of Biological Chemistry (United States) 2005, 280:17458-17463.
168. Morris M., Maeda S., Vossel K., Mucke L. The many faces of tau. Neuron 2011, 70:410-426.
169. Mosconi L., De S.S., Li J., Tsui W.H., Li Y., Boppana M., et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of Aging 2008, 29:676-692.
170. Mu Y., Gage F.H. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Molecular Neurodegeneration (England) 2011, 6:85.
171. Muhammad A., Flores I., Zhang H., Yu R., Staniszewski A., Planel E., et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proceedings of the National Academy of Sciences of the United States of America (United States) 2008, 105:7327-7332.
172. Muresan V., Varvel N.H., Lamb B.T., Muresan Z. The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. Journal of Neuroscience (United States) 2009, 29:3565-3578.
173. Nagele E., Han M., Demarshall C., Belinka B., Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One (United States) 2011, 6:e23112.
174. Nagele R.G., Clifford P.M., Siu G., Levin E.C., Acharya N.K., Han M., et al. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta(1-42) deposition. Journal of Alzheimer's Disease (Netherlands) 2011, 25:605-622.
175. Nakamura T., Watanabe A., Fujino T., Hosono T., Michikawa M. Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Molecular Neurodegeneration (England) 2009, 4:35.
176. Nath A., Hall E., Tuzova M., Dobbs M., Jons M., Anderson C., et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: Implications for disease pathogenesis and vaccine development. Neuromolecular Medicine (United States) 2003, 3:29-39.
177. Newhouse P., Kellar K., Aisen P., White H., Wesnes K., Coderre E., et al. Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology 2012, 78:91-101.
178. Nielsen M.S., Gustafsen C., Madsen P., Nyengaard J.R., Hermey G., Bakke O., et al. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Molecular Cell Biology (United States) 2007, 27:6842-6851.
179. Nitsch R.M., Hock C. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics (United States) 2008, 5:415-420.
180. Nixon R.A., Yang D.S. Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiology of Disease (United States) 2011, 43:38-45.
181. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. Journal of Neuropathology and Experimental Neurology (United States) 2005, 64:113-122.
182. Nykjaer A., Lee R., Teng K.K., Jansen P., Madsen P., Nielsen M.S., et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature (England) 2004, 427:843-848.
183. Offe K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I., et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. Journal of Neuroscience (United States) 2006, 26:1596-1603.
184. Olgiati P., Politis A.M., Papadimitriou G.N., De Ronchi D., Serretti A., et al. Genetics of late-ons zheimer's disease: Update from the alzgene database and analysis of shared pathways. International Journal of Alzheimer's Disease (United States) 2011, 2011:832379.
185. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: The rotterdam study. Diabetologia (Germany) 1996, 39:1392-1397.
186. Pandya J.D., Pauly J.R., Nukala V.N., Sebastian A.H., Day K.M., Korde A.S., et al. Post-injury administration of mitochondrial uncouplers increases tissue sparing and improves behavioral outcome following traumatic brain injury in rodents. Journal of Neurotrauma 2007, 24:798-811.
187. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., et al. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiology of Aging (United States) 2005, 26:995-1000.
188. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 alzheimer mice. Experimental Neurology 2006, 199:265-273.
189. Pedersen K.M., Hermey G., Kjolby M., Skeldal S., Vaegrer C., Nykjaer A. SorCS1 and type 2 diabetes mellitus. Sortilins: Sorting and Disease Abstract form #25 2010.
190. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., Agis-Balboa R.C., et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328:753-756.
191. Peng S., Wuu J., Mufson E.J., Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. Journal of Neuropathology and Experimental Neurology (United States) 2004, 63:641-649.
192. Perez-Garmendia R., Ibarra-Bracamontes V., Vasilevko V., Luna-Munoz J., Mena R., Govezensky T., et al. Anti-11[E]-pyroglutamate-modified amyloid beta antibodies cross-react with other pathological Abeta species: Relevance for immunotherapy. Journal of Neuroimmunology (Netherlands) 2010, 229:248-255.
193. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
194. Pieper A.A., Wu X., Han T.W., Estill S.J., Dang Q., Wu L.C., et al. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proceedings of the National Academy of Sciences of the United States of America (United States) 2005, 102:14052-14057.
195. Pieper A.A., et al. Discovery of a proneurogenic, neuroprotective chemical. Cell (United States) 2010, 142:39-51.
196. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clinical Neuropharmacology 1998, 21:141-151.
197. Planel E., Tatebayashi Y., Miyasaka T., Liu L., Wang L., Herman M., et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. Journal of Neuroscience 2007, 27:13635-13648.
198. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. Journal of Clinical Investigation (United States) 2004, 113:1456-1464.
199. Rajendran L., Honsho M., Zahn T.R., Keller P., Geiger K.D., Verkade P., et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proceedings of the National Academy of Sciences of the United States of America (United States) 2006, 103:11172-11177.
200. Ramaswamy G., Xu Q., Huang Y., Weisgraber K.H. Effect of domain interaction on apolipoprotein E levels in mouse brain. Journal of Neuroscience (United States) 2005, 25:10658-10663.
201. Reitz C. The family of VPS10 receptors: Genetic links to Alzheimer's disease. International conference on Alzheimer's disease F2-01-01 Paris 2011.
202. Reitz C., Lee J.H., Rogers R.S., Mayeux R. Impact of genetic variation in SORCS1 on memory retention. PLoS One (United States) 2011, 6:e24588.
203. Reitz C., Tokuhiro S., Clark L.N., Conrad C., Vonsattel J.P., Hazrati L.N., et al. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Annals of Neurology (United States) 2011, 69:47-64.
204. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology 2009, 202:419-443.
205. Renner M., Lacor P.N., Velasco P.T., Xu J., Contractor A., Klein W.L., et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010, 66:739-754.
206. Restrepo L., Stafford P., Magee D.M., Johnston S.A. Application of immunosignatures to the assessment of Alzheimer's disease. Annals of Neurology (United States) 2011, 70:286-295.
207. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. Journal of Neuroscience (United States) 2008, 28:11445-11453.
208. Riddell D.R., et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Molecular and Cellular Neurosciences (United States) 2007, 34:621-628.
209. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology (England) 2010, 9:363-372.
210. Roberts R.O., Geda Y.E., Knopman D.S., Boeve B.F., Christianson T.J., Pankratz V.S., et al. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement (United States) 2009, 5:398-405.
211. Rogaeva E., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics (United States) 2007, 39:168-177.
212. Sadowski M., Pankiewicz J., Scholtzova H., Ripellino J.A., Li Y., Schmidt S.D., et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. American Journal of Pathology (United States) 2004, 165:937-948.
213. Sadowski M.J., Pankiewicz J., Scholtzova H., Mehta P.D., Prelli F., Quartermain D., et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America (United States) 2006, 103:18787-18792.
214. Sager K.L., Wuu J., Leurgans S.E., Rees H.D., Gearing M., Mufson E.J., et al. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Annals of Neurology (United States) 2007, 62:640-647.
215. Sahay A., Scobie K.N., Hill A.S., O'Carroll C.M., Kheirbek M.A., Burghardt N.S., et al. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature (England) 2011, 472:466-470.
216. Sanchez-Ramos J., Song S., Cao C., Arendash G. The potential of hematopoietic growth factors for treatment of Alzheimer's disease: A mini-review. BMC Neuroscience (England) 2008, 9(Suppl. 2):S3.
217. Sanchez-Ramos J., Song S., Sava V., Catlow B., Lin X., Mori T., et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience (United States) 2009, 163:55-72.
218. Saxena S., Bucci C., Weis J., Kruttgen A. The small GTPase Rab7 controls the endosomal trafficking and neuritogenic signaling of the nerve growth factor receptor TrkA. Journal of Neuroscience (United States) 2005, 25:10930-10940.
219. Saxena S., Howe C.L., Cosgaya J.M., Steiner P., Hirling H., Chan J.R., et al. Differential endocytic sorting of p75NTR and TrkA in response to NGF: A role for late endosomes in TrkA trafficking. Molecular and Cellular Neurosciences (United States) 2005, 28:571-587.
220. Scheibel M.E., Lindsay R.D., Tomiyasu U., Scheibel A.B. Progressive dendritic changes in aging human cortex. Experimental Neurology 1975, 47:392-403.
221. Scherzer C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Archives of Neurology (United States) 2004, 61:1200-1205.
222. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology (England) 2007, 18:391-418.
223. Schmidt V., Sporbert A., Rohe M., Reimer T., Rehm A., Andersen O.M., et al. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. Journal of Biological Chemistry (United States) 2007, 282:32956-32964.
224. Selkoe D.J. Presenilin, notch, and the genesis and treatment of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America (United States) 2001, 98:11039-11041.
225. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
226. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural Brain Research 2008, 192:106-113.
227. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. Journal of Neuroscience (United States) 2007, 27:2866-2875.
228. Shineman D.W., Basi G.S., Bizon J.L., Colton C.A., Greenberg B.D., Hollister B.A., et al. Accelerating drug discovery for Alzheimer's disease: Best practices for preclinical animal studies. Alzheimer's Research & Therapy 2011, 3:28.
229. Shirey J.K., Brady A.E., Jones P.J., Davis A.A., Bridges T.M., Kennedy J.P., et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. Journal of Neuroscience 2009, 29:14271-14286.
230. Sigurdsson E.M. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Current Alzheimer Research (United Arab Emirates) 2009, 6:446-450.
231. Small S.A., Gandy S. Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron (United States) 2006, 52:15-31.
232. Solano D.C., Sironi M., Bonfini C., Solerte S.B., Govoni S., Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB Journal (United States) 2000, 14:1015-1022.
233. Storace D., Cammarata S., Borghi R., Sanguineti R., Giliberto L., Piccini A., et al. Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Archives of Neurology (United States) 2010, 67:867-872.
234. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America (United States) 1993, 90:1977-1981.
235. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onszheimer disease. Proceedings of the National Academy of Sciences of the United States of America (United States) 1993, 90:8098-8102.
236. Swardfager W., Lanctot K., Rothenburg L., Wong A., Cappell J., Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biological Psychiatry (United States) 2010, 68:930-941.
237. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmunity Reviews (Netherlands) 2008, 7:415-420.
238. Tai L.M., Youmans K.L., Jungbauer L., Yu C., Ladu M.J. Introducing human APOE into Abeta transgenic mouse models. International Journal of Alzheimer's Disease (United States) 2011, 2011:810981.
239. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proceedings of the National Academy of Sciences of the United States of America (United States) 2010, 107:7036-7041.
240. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: Insights into insulin action. Nature Reviews. Molecular Cell Biology (England) 2006, 7:85-96.
241. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment 1991, 30:572-580.
242. Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. Journal of Biological Chemistry (United States) 2008, 283:29615-29619.
243. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochemistry of Journal (England) 348 Pt 2000, 2:359-365.
244. Trepanier C.H., Milgram N.W. Neuroinflammation in Alzheimer's disease: Are NSAIDs and selective COX-2 inhibitors the next line of therapy?. Journal of Alzheimer's Disease (Netherlands) 2010, 21:1089-1099.
245. Tukhovskaya E.A., Yukin A.Y., Khokhlova O.N., Murashev A.N., Vitek M.P. COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. Journal of Neuroscience Research (United States) 2009, 87:677-682.
246. Tweedie D., Sambamurti K., Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: New drug candidates and targets. Current Alzheimer Research (United Arab Emirates) 2007, 4:378-385.
247. Vacirca D., Delunardo F., Matarrese P., Colasanti T., Margutti P., Siracusano A., et al. Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease. Neurobiology of Aging 2010, 33(4):753.
248. Vallejo A.N. Immunological hurdles of ageing: Indispensable research of the human model. Ageing Research Reviews (England) 2011, 10:315-318.
249. van Eersel E.J., Ke Y.D., Liu X., Delerue F., Kril J.J., Gotz J., et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:13888-13893.
250. van Praag H., Christie B.R., Sejnowski T.J., Gage F.H. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proceedings of the National Academy of Sciences of the United States of America (United States) 1999, 96:13427-13431.
251. Vellas B., Sol O., Snyder P.J., Ousset P.J., Haddad R., Maurin M., et al. EHT0202 in Alzheimer's disease: A 3-month, randomized, placebo-controlled, double-blind study. Current Alzheimer Research 2011, 8:203-212. group EHTs.
252. Voronkov M., Braithwaite S.P., Stock J.B. Phosphoprotein phosphatase 2A: A novel druggable target for Alzheimer's disease. Future Medicinal Chemistry 2011, 3:821-833.
253. Wang H., Larriviere K.S., Keller K.E., Ware K.A., Burns T.M., Conaway M.A., et al. R+ pramipexole as a mitochondrially focused neuroprotectant: Initial early phase studies in ALS. Amyotrophic Lateral Sclerosis 2008, 9:50-58.
254. Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America (United States) 2010, 107:6498-6503.
255. Wang X., Zheng W., Xie J.W., Wang T., Wang S.L., Teng W.P., et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Molecular Neurodegeneration (England) 2010, 5:46.
256. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. American Journal of Geriatric Psychiatry 2005, 13:950-958.
257. Watterson D.M., Mirzoeva S., Guo L., Whyte A., Bourguignon J.J., Hibert M., et al. Ligand modulation of glial activation: Cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin 1 beta and nitric oxide synthase II. Neurochemistry International (England) 2001, 39:459-468.
258. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Experimental Gerontology (England) 2002, 37:943-948.
259. Wen L., Tang F.L., Hong Y., Luo S.W., Wang C.L., He W., et al. VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. Journal of Cell Biology (United States) 2011, 195:765-779.
260. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11213-11218.
261. Wisniewski T., Castano E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. American Journal of Pathology (United States) 1994, 145:1030-1035.
262. Xing Y., Li Z., Chen Y., Stock J.B., Jeffrey P.D., Shi Y. Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 2008, 133:154-163.
263. Xu P.T., Gilbert J.R., Qiu H.L., Ervin J., Rothrock-Christian T.R., Hulette C., et al. Specific regional transcription of apolipoprotein E in human brain neurons. American Journal of Pathology (United States) 1999, 154:601-611.
264. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R.W., Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. Journal of Neuroscience (United States) 2006, 26:4985-4994.
265. Yanagisawa K. Pathological significance of ganglioside clusters in Alzheimer's disease. Journal of Neurochemistry (England) 2011, 116:806-812.
266. Yang D.S., Stavrides P., Mohan P.S., Kaushik S., Kumar A., Ohno M., et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy (United States) 2011, 7:788-789.
267. Yang D.S., Stavrides P., Mohan P.S., Kaushik S., Kumar A., Ohno M., et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (England) 2011, 134:258-277.
268. Yang T., Knowles J.K., Lu Q., Zhang H., Arancio O., Moore L.A., et al. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One 2008, 3:e3604.
269. Yao J., Chen S., Mao Z., Cadenas E., Brinton R.D. 2-deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS One 2011, 6:e21788.
270. Yu W.H., Kumar A., Peterhoff C., Shapiro Kulnane L., Uchiyama Y., Lamb B.T., et al. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: Implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. International Journal of Biochemistry & Cell Biology (England) 2004, 36:2531-2540.
271. Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., et al. Macroautophagy-a novel beta-amyloid peptide-generating pathway activated in alzheimer's disease. Journal of Cell BiologyJ Cell Biol (United States) 2005, 171:87-98.
272. Yuzwa S.A., Macauley M.S., Heinonen J.E., Shan X., Dennis R.J., He Y., et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nature Chemical Biology 2008, 4:483-490.
273. Zhang B., Maiti A., Shively S., Lakhani F., McDonald-Jones G., Bruce J., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:227-231.
274. Zhao C.J., Noack C., Brackmann M., Gloveli T., Maelicke A., Heinemann U., et al. Neuronal Ca2+ sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. Molecular and Cellular Neurosciences 2009, 40:280-292.
275. Zhong N., Scearce-Levie K., Ramaswamy G., Weisgraber K.H. Apolipoprotein E4 domain interaction: Synaptic and cognitive deficits in mice. Alzheimer's & Dementia (United States) 2008, 4:179-192.
276. Zhou Z., Smith J.D., Greengard P., Gandy S. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Molecular Medicine (United States) 1996, 2:175-180.
277. Zhou Z.D., Chan C.H., Ma Q.H., Xu X.H., Xiao Z.C., Tan E.K. The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease. Cell Adhesion & Migration (United States) 2011, 5:280-292.
278. Zweig R.M., Ross C.A., Hedreen J.C., Steele C., Cardillo J.E., Whitehouse P.J., et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Annals of Neurology 1988, 24:233-242.